COMPANY PROFILE

Revalesio

Explore full profile

A clinical-stage pharmaceutical company that develops therapeutics for the treatment of inflammatory diseases

Tacoma, United StatesFounded 2000Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Revalesio

Revalesio is a clinical-stage pharmaceutical company that is focused on developing treatments for acute and chronic neurological disorders. The company's primary area of research is on acute ischemic stroke, a leading cause of disability and the second leading cause of death worldwide. Revalesio is also exploring treatments for other neurological conditions such as amyotrophic lateral sclerosis (ALS).

The company has developed a proprietary technology platform that utilizes the principles of fluid physics to create a new class of drugs. Their lead product candidate, RNS60, is designed to protect mitochondria and has shown promise in preclinical models of ALS. The business model is centered around the research and development of these novel therapeutics, with the ultimate goal of bringing them to market to improve patient outcomes. The company likely generates revenue through partnerships, licensing agreements, and eventually, the sale of its approved drugs.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2000
Headquarters: Tacoma, United States
Employees: 21
Open positions: None listed
Dealroom signal: 60.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Jun 2022	$15M	$60M	Undisclosed	↗
EARLY VCOther financing	Jul 2016	$14M	$56M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Revalesio website traffic

Latest recorded traffic for Revalesio is 1.3K monthly website visits, up 30% over the last three months. Revalesio's team grew 0% over the past year.

Latest monthly visits1.3K 3-month web change+30% 1-year team growth0%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational	21	$77M	$335M
PBPhageNova BioPioneering Targeted Gene Expression For Cancer and Vaccines	Summit, United States	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
RPRivus PharmaceuticalsOperates as a biopharmaceutical company dedicated to improving cardio-metabolic health	Charlottesville, United States	Operational
KTKintsugi TherapeuticsDevelopment of ER stress inhibitors for the treatment of metabolic diseases	Barcelona, Spain	Operational
GAGalixirOffering pharmaceutical companies with accesses to faster and better drug discovery methods, as well as strong patent protections on drug	Dongcheng District, China	Operational
BPBeckley PsytechClinical-stage biotechnology developing rapid-acting psychedelic medicines	Beckley and Stowood, United Kingdom	Operational
XIXilisDeveloping next generation technologies for precision medicine and drug discovery	Durham, United States	Operational